AR062684A1 - Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos - Google Patents

Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos

Info

Publication number
AR062684A1
AR062684A1 ARP070103941A ARP070103941A AR062684A1 AR 062684 A1 AR062684 A1 AR 062684A1 AR P070103941 A ARP070103941 A AR P070103941A AR P070103941 A ARP070103941 A AR P070103941A AR 062684 A1 AR062684 A1 AR 062684A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydroxy
carboxylic acid
carboxy
och2
Prior art date
Application number
ARP070103941A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR062684A1 publication Critical patent/AR062684A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Dichos compuestos actuan particularmente como agentes inmunomoduladores. Reivindicacion 1: Un compuesto de la Formula (1) en donde A representa *-CONH-CH2-, *-CO-CH=CH-, *-CO-CH2CH2-, grupo de formulas (2) donde los asteriscos indican el enlace donde ésta se une al grupo piridina de Formula 1; R1 representa hidrogeno, C1-4-alquil, o cloro; R2 representa C1-5-alquil o C1-4-alcoxi; R3 representa hidrogeno, C1-4-alquil, C1-4alcoxi, o halogeno; R4 representa hidrogeno, C1-4-alquil, C1-4- alcoxi, halogeno, trifluormetil o trifluormetoxi; R5 representa 2,3-dihidroxipropil, di-(hidroxi-C1-4-alquil)-C1-4-alquil, -CH2-(CH2)kNHSO2R53, -(CH2)nCH(OH)-CH2-NHSO2R53, -CH2-(CH2)k-NHCOR54, -(CH2)nCH(OH)-CH2-NHCOR54, -CH2-(CH2)n-CONR51R52, -CO- NHR51, 1-(3-carboxi-azetidinil)-2-acetil, 1-(2-carboxi-pirrolidinil)-2-acetil, 1-(3-carboxi-pirrolidinil)-2-acetil, 1-(3-carboxi-azetidinil)-3-propionil, 1-(2-carboxi-pirrolidinil)-3-propionil, 1-(3-carboxi-pirrolidinil)-3-propionil, -(CH2)nCH(OH)- CH2-NR51R52, hidroxi, hidroxi-C2-5-alcoxi, di-(hidroxi-C1-4-alquil)-C1-4-alcoxi, 2,3-dihidroxi-propoxi, 2-hidroxi-3-metoxi-propoxi, -OCH2-(CH2)m-NR51R52, 2-[(azetidina-3-ácido carboxílico)-1-il]-etoxi, 2-[(azetidina-3-ácido carboxílico C1-5- alquiléster)-1-il]-etoxi, 2-[(pirrolidina-3-ácido carboxílico)-1-il]-etoxi, 2-[(pirrolidina-3-ácido carboxílico C1-5-alquiléster)-1-il]-etoxi, -OCH2-CH(OH)-CH2-NR51R52, 3-[(azetidina-3-ácido carboxílico)-1-il]-2-hidroxipropoxi, 3-[(azetidina-3-ácido carboxílico C1-5-alquiléster)-1-il]-2-hidroxipropoxi, 2-hidroxi-3-[(pirrolidina-3-ácido carboxílico)-1-il]-propoxi, 2-hidroxi-3-[(pirrolidina-3- ácido carboxílico C1-5-alquiléster)-1-il]propoxi, 2-hidroxi-3-[(pirrolidina-2- ácido carboxílico)-1-il]- propoxi, 2-hidroxi-3-[(pirrolidina-2- ácido carboxílico C1-5-alquiléster)-1-il]-propoxi, -OCH2-(CH2)m-NHSO2R53, -OCH2-CH(OH)-CH2-NHSO2R53, -OCH2-(CH2)m-NHCOR54, -OCH2-CH(OH)-CH2-NHCOR54; R51 representa hidrogeno, C1-3-alquil, 2-hidroxietil, 2- hidroxi-1-hidroximetil-etil, 2,3-dihidroxipropil, carboximetil, 1-(C1-5-alquilcarboxi)metil, 2-carboxietil, o 2-(C1-5-alquilcarboxi)etil; R52 representa hidrogeno, metil, o etil; R53 representa C1-3-alquil, metilamino, etilamino, o dimetilamino; R54 representa hidroximetil, hidroxietil, aminometil, metilaminometil, dimetilaminometil, aminoetil, 2-metilaminoetil, o 2-dimetilamino-etil; k representa el numero entero 1, 2, o 3; m representa el numero entero 1 o 2; n representa 0, 1, o 2; y R6 representa hidrogeno, C1-4-alquil o halogeno, y una sal de tal compuesto.
ARP070103941A 2006-09-08 2007-09-06 Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos AR062684A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006053187 2006-09-08

Publications (1)

Publication Number Publication Date
AR062684A1 true AR062684A1 (es) 2008-11-26

Family

ID=38982768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103941A AR062684A1 (es) 2006-09-08 2007-09-06 Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos

Country Status (27)

Country Link
US (1) US8288554B2 (es)
EP (1) EP2069335B1 (es)
JP (1) JP5253400B2 (es)
KR (1) KR101454937B1 (es)
CN (1) CN101522670B (es)
AR (1) AR062684A1 (es)
AU (1) AU2007292992B2 (es)
BR (1) BRPI0716633A2 (es)
CA (1) CA2661315C (es)
CL (1) CL2007002594A1 (es)
CY (1) CY1113858T1 (es)
DK (1) DK2069335T3 (es)
ES (1) ES2400163T3 (es)
HK (1) HK1135976A1 (es)
HR (1) HRP20130180T1 (es)
IL (1) IL197394A (es)
MA (1) MA30717B1 (es)
MX (1) MX2009002234A (es)
MY (1) MY150661A (es)
NO (1) NO20091409L (es)
NZ (1) NZ576059A (es)
PL (1) PL2069335T3 (es)
PT (1) PT2069335E (es)
RU (1) RU2454413C2 (es)
SI (1) SI2069335T1 (es)
TW (1) TWI399371B (es)
WO (1) WO2008029370A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
KR101454937B1 (ko) 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
US8044076B2 (en) * 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
SG177221A1 (en) * 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
EP2125797B1 (en) * 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
WO2009024905A1 (en) * 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
TW200920746A (en) * 2007-11-01 2009-05-16 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
US20110028448A1 (en) * 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
EP2262800A1 (en) * 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Novel pyrimidine-pyridine derivatives
PL2252609T3 (pl) * 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące
CA2715317A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
PT2278960T (pt) 2008-03-17 2017-03-09 Actelion Pharmaceuticals Ltd Regime de dosagem para um agonista seletivo do recetor s1p1
EP2177521A1 (en) * 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
DE102008063561A1 (de) 2008-12-18 2010-08-19 Bayer Cropscience Ag Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
WO2010100142A1 (en) * 2009-03-03 2010-09-10 Merck Serono S.A. Oxazole pyridine derivatives useful as s1p1 receptor agonists
DE102009002514A1 (de) * 2009-04-21 2010-10-28 Evonik Degussa Gmbh Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
DK2427416T3 (en) * 2009-05-04 2016-06-13 Prometic Pharma Smt Ltd Substituted aromatic compounds, and pharmaceutical uses thereof
GB0911130D0 (en) * 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
US20120101134A1 (en) * 2009-06-26 2012-04-26 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
SG178042A1 (en) 2009-07-16 2012-03-29 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
WO2011059784A1 (en) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
JP5788507B2 (ja) 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換３−フェニル−１，２，４−オキサジアゾール化合物
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
US8629282B2 (en) 2010-11-03 2014-01-14 Bristol-Myers Squibb Company Heterocyclic compounds as S1P1 agonists for the treatment of autoimmune and vascular diseases
PT2665720E (pt) 2011-01-19 2015-09-16 Actelion Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
US9000016B2 (en) 2012-11-05 2015-04-07 Allergan, Inc. 1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
UA115357C2 (uk) 2013-03-15 2017-10-25 Ідорсія Фармасьютікалз Лтд Похідні піридин-4-ілу
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
WO2015073140A1 (en) * 2013-11-14 2015-05-21 Allergan, Inc. 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015108577A1 (en) * 2014-01-15 2015-07-23 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
EP3298008B1 (en) 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
EP4291183A1 (en) * 2021-02-10 2023-12-20 Icahn School of Medicine at Mount Sinai Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
CA2051494C (en) 1990-09-20 2006-03-14 Robert J. Dinerstein 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors
DE4429465A1 (de) * 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
RU2319701C2 (ru) 2001-02-21 2008-03-20 Астразенека Аб ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) * 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20060252741A1 (en) 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
AU2005247110B2 (en) 2004-05-29 2010-08-26 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
WO2006010379A1 (en) * 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
EP1804793A4 (en) 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
KR101262400B1 (ko) * 2004-12-13 2013-05-08 오노 야꾸힝 고교 가부시키가이샤 아미노카르복실산 유도체 및 그 의약 용도
CA2602478A1 (en) * 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
KR20070116645A (ko) 2005-03-23 2007-12-10 액테리온 파마슈티칼 리미티드 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체
KR101382733B1 (ko) 2005-03-23 2014-04-14 액테리온 파마슈티칼 리미티드 면역조절물질로서의 수첨 벤조(ｃ) 티오펜 유도체
CN101203512A (zh) * 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
JP2008539195A (ja) 2005-04-26 2008-11-13 ノイロサーチ アクティーゼルスカブ 新規のオキサジアゾール誘導体及びそれらの医学的使用
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135694A2 (en) * 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
KR20080024533A (ko) * 2005-06-24 2008-03-18 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
US20090054491A1 (en) 2005-06-28 2009-02-26 Astrazeneca Ab Use
AR057894A1 (es) * 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) * 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
CN101384566A (zh) 2006-02-21 2009-03-11 弗吉尼亚大学专利基金会 作为s1p受体激动剂的苯基-环烷基和苯基-杂环衍生物
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
AR061841A1 (es) * 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
KR101454937B1 (ko) 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
US8044076B2 (en) 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
MX2009003129A (es) 2006-09-29 2009-04-06 Novartis Ag Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
UA91793C2 (ru) * 2006-10-07 2010-08-25 Смс Зимаг Акциенгезелльшафт Способ эксплуатации конвертера
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20080138955A1 (en) * 2006-12-12 2008-06-12 Zhiyuan Ye Formation of epitaxial layer containing silicon
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
EP2125797B1 (en) * 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
WO2009024905A1 (en) 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
TW200920746A (en) 2007-11-01 2009-05-16 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
ES2403209T3 (es) * 2007-12-10 2013-05-16 Actelion Pharmaceuticals Ltd. Derivados de tiofeno novedosos como agonistas de S1P1/EDG1
US20110028448A1 (en) * 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
EP2262800A1 (en) * 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Novel pyrimidine-pyridine derivatives
CA2715317A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
PL2252609T3 (pl) * 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące

Also Published As

Publication number Publication date
CA2661315A1 (en) 2008-03-13
AU2007292992A1 (en) 2008-03-13
US20100168005A1 (en) 2010-07-01
NZ576059A (en) 2012-03-30
NO20091409L (no) 2009-04-07
EP2069335A1 (en) 2009-06-17
KR101454937B1 (ko) 2014-10-27
DK2069335T3 (da) 2013-02-18
IL197394A (en) 2013-08-29
SI2069335T1 (sl) 2013-04-30
CA2661315C (en) 2015-11-24
JP5253400B2 (ja) 2013-07-31
HRP20130180T1 (hr) 2013-03-31
CL2007002594A1 (es) 2008-06-06
CN101522670A (zh) 2009-09-02
RU2009112726A (ru) 2010-10-20
EP2069335B1 (en) 2012-12-26
JP2010502694A (ja) 2010-01-28
WO2008029370A1 (en) 2008-03-13
KR20090060327A (ko) 2009-06-11
CY1113858T1 (el) 2016-07-27
BRPI0716633A2 (pt) 2013-09-24
MY150661A (en) 2014-02-14
HK1135976A1 (en) 2010-06-18
AU2007292992B2 (en) 2013-01-10
ES2400163T3 (es) 2013-04-08
US8288554B2 (en) 2012-10-16
MA30717B1 (fr) 2009-09-01
PL2069335T3 (pl) 2013-05-31
IL197394A0 (en) 2009-12-24
TW200817358A (en) 2008-04-16
PT2069335E (pt) 2013-03-04
TWI399371B (zh) 2013-06-21
RU2454413C2 (ru) 2012-06-27
CN101522670B (zh) 2012-05-23
MX2009002234A (es) 2009-03-16

Similar Documents

Publication Publication Date Title
AR062684A1 (es) Compuestos derivados de piridin-3- ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AR062683A1 (es) Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
ATE554085T1 (de) Neue inhibitoren von glutaminylcyclase
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
UY29457A1 (es) Compuestos novedosos de derivados de aminosulfonilo
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
PE20060259A1 (es) Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
DE602007011302D1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
AR078756A1 (es) Moduladores alostericos positivos (map)
UY30387A1 (es) Nuevos compuestos
ATE455113T1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors
PE20080364A1 (es) Acido bifenilcarboxilicos substituidos y sus derivados como moduladores de la actividad de la gamma-secretasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure